Rocket Pharmaceuticals, Inc. Common Stock
Here’s whether Rocket Pharmaceuticals, Inc. Common Stock (RCKT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-8.09% over 10 days); weak 1-year return of -54.9%; 3-month momentum negative (-30.4%). Currently 56.5% off its 52-week high. Score: -6/7.
RCKT is trading below its 200-day MA ($3.57) — a key warning sign the longer-term trend is under pressure. An RSI of 31.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -54.9% compares to +27.9% for SPY (trailed the market by 82.8%). The current 56.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.